figure s1 a. neutrophilsb. non-inflammatory monocytes c. macrophages or dcs d. inflammatory...
TRANSCRIPT
Figure S1
a. Neutrophils b. Non-inflammatory monocytes
c. Macrophages or DCs
d. Inflammatory monocytes
SS
C
FSC
B
C
SS
C
**
*
**
I II
Co
un
t
F4/80
A
A
B
De
ns
ito
me
try
un
itD
en
sit
om
etr
y u
nit
pNF-ĸB p65
pSTAT3
Figure S2
IKKβΔMyeC57BL/6
Den
sito
met
ry u
nit
pSTAT3pNF-ĸB p65
PBS(3 hours)
EdTx(6 hours)
C57BL/6IKKβΔMyeTreatment
(time)
EdTx(3 hours)
C57BL/6IKKβΔMye
C57BL/6IKKβΔMye
Figure S3
CCL2
CXCL2
**
*
**
*
* * **
Re
lati
ve
mR
NA
le
ve
ls
(20
― ∆
Ct)
Figure S4
Re
lati
ve
mR
NA
le
ve
ls
(20
― ∆
Ct)
B
A
*
Ab
tit
ers
(L
og
2GM
Ts
) PA-specific neutralizing Abs
Ab
tit
ers
(L
og
2G
MT
s)
PA-specific serum IgG titersA
*
B
Figure S5
F1
V-s
pe
cif
ic
Ab
tit
ers
(Lo
g2G
MT
s) C57BL/6
IKKβΔMye
Figure S6
Serum IgA
F1
V-s
pe
cif
ic
Ab
tit
ers
(Lo
g2G
MT
s)
Fecal IgA
A
B
C57BL/6IKKβΔMye
Figure S7
CD11b+F4/80–Gr-1high
(Neutrophils)
Fre
qu
en
cy
(%
) in
my
elo
id c
ell
s
Days after injection
A
B
CD11b+F4/80–Gr-1high
(Neutrophils)
Fre
qu
en
cy
(%
)in
my
elo
id c
ell
s
CD11b+F4/80+Gr-1high
(Inflammatory monocytes)
CD11b+F4/80+Gr-1low
(Macrophages or DCs)
Fre
qu
en
cy
(%
)in
my
elo
id c
ell
s
CD11b+F4/80+Gr-1─
(Non-inflammatory monocytes)
Figure S8
Fre
qu
ency
(%
)
B220+IL-17RAlow B220+IL-17RAhighB▼
*
*▼
▼*▼
*
C57BL/6 CD11b+ IKKβΔMye CD11b+
EdTx
+–
–
–+
–
–+
+
+–
+
+–
–
–+
–
–+
+
+–
+
FS
C
IL-17RA
AIL-17RAlow
IL-17RAhigh
APRIL
BAFF
AID
*
▼▼
▼
▼
*▼
▼
Rel
ativ
e m
RN
A l
evel
s (2
0 ―
∆C
t)
C57BL/6 CD11b+ IKKβΔMye CD11b+
EdTx
+–
–
–+
–
–+
+
+–
+
C
Pro
-in
fla
mm
ato
ry
cy
tok
ine
m
RN
As
(2
0 ―
∆C
t)
An
ti-i
nfl
am
ma
tory
Cy
tok
ine
mR
NA
s
(20
― ∆
Ct)
IL-1β IL-6
C57BL/6 CD11b+
IKKΔ Mye CD11b+ + +– –
+– +––– ++EdTx
+ +– –+– +––– ++
*
▼ ▼▼ ▼
En
zym
e m
RN
As
(20
― ∆
Ct)
Caspase-1*
▼
IL-10 TGF-
*
*▼ ▼
Figure S9
TNF-α IL-23
▼
▼
**
▼*
C57BL/6 CD11b+
IKKΔ Mye CD11b+ + +– –
+– +––– ++EdTx
+ +– –+– +––– ++
C57BL/6 CD11b+
IKKΔ Mye CD11b+ + +– –
+– +––– ++EdTx
A
B
C